Cartesian Therapeutics (RNAC) Change in Receivables (2015 - 2026)
Cartesian Therapeutics' (RNAC) quarterly Change in Receivables came in at -$854000.0 in Q1 2026, down 195.63% year-on-year from $893000.0 in Q1 2025, and down 317.3% on a QoQ basis from $393000.0 in Q4 2025.
Cartesian Therapeutics (RNAC) Change in Receivables (2015 - 2026) Analysis & Trends
Cartesian Therapeutics (RNAC) has 12 years of Change in Receivables data on file, last reported at -$854000.0 in Q1 2026.
- On a quarterly basis, Change in Receivables fell 195.63% year-over-year to -$854000.0 in Q1 2026; TTM through Mar 2026 was -$1.5 million, a 524.07% decrease from a year earlier, with the FY2025 full-year figure at $243000.0, up 104.86% from the prior year.
- Change in Receivables for Q1 2026 stood at -$854000.0, down from $393000.0 in the prior quarter.
- Over the last five years, Change in Receivables for RNAC reached as high as $30.0 million in Q2 2024 and fell as low as -$27.2 million in Q3 2024.
- Historically, Change in Receivables has averaged -$567823.5 across 5 years, with a median of -$487000.0 in 2023.
- Across the five-year window, Change in Receivables jumped 13591.87% in 2022 and slumped 5487.27% in 2024, its largest moves.
- Year by year, Change in Receivables stood at -$329000.0 in 2022, then jumped by 395.44% to $972000.0 in 2023, then sank by 507.1% to -$4.0 million in 2024, then jumped by 109.93% to $393000.0 in 2025, then sank by 317.3% to -$854000.0 in 2026.
- Per Business Quant data, the three most recent Change in Receivables figures were -$854000.0 in Q1 2026, $393000.0 in Q4 2025, and $368000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 75.30 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 2.84 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | -39.80 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -1.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Cartesian Therapeutics | 226.07 Mn | 226.07 Mn | - | -854,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -854,000.00 |
| Mar 31, 2026 | -854,000.00 |
| Dec 31, 2025 | 393,000.00 |
| Dec 31, 2025 | 393,000.00 |
| Sep 30, 2025 | 368,000.00 |
| Sep 30, 2025 | 368,000.00 |
| Jun 30, 2025 | -1.41 Mn |
| Jun 30, 2025 | -1.41 Mn |
| Mar 31, 2025 | 893,000.00 |
| Mar 31, 2025 | 893,000.00 |
| Dec 31, 2024 | -3.96 Mn |
| Dec 31, 2024 | -3.96 Mn |
| Sep 30, 2024 | -27.21 Mn |
| Sep 30, 2024 | -27.21 Mn |
| Jun 30, 2024 | 30.03 Mn |
| Jun 30, 2024 | 30.03 Mn |
| Mar 31, 2024 | -3.86 Mn |
| Mar 31, 2024 | -3.86 Mn |
| Dec 31, 2023 | 972,000.00 |
| Dec 31, 2023 | 972,000.00 |